{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:02:03Z","timestamp":1774954923951,"version":"3.50.1"},"reference-count":161,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.heliyon.2023.e22214","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T23:55:21Z","timestamp":1699660521000},"page":"e22214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances and Perspectives in methods for identifying high platelet reactivity"],"prefix":"10.1016","volume":"9","author":[{"given":"Hua","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoshan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8353-2314","authenticated-orcid":false,"given":"Ning","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7329","key":"10.1016\/j.heliyon.2023.e22214_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"issue":"27","key":"10.1016\/j.heliyon.2023.e22214_bib2","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e22214_bib3","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jacc.2008.05.032","article-title":"Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents","volume":"52","author":"Gori","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e22214_bib4","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Working Group on High On-Treatment Platelet Reactivity, Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.heliyon.2023.e22214_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.vph.2016.05.010","article-title":"Clinical significance of residual platelet reactivity in patients treated with platelet P2Y12 inhibitors","volume":"84","author":"Thomas","year":"2016","journal-title":"Vascul Pharmacol"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e22214_bib6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/eurheartj\/eht375","article-title":"Working Group on Thrombosis of the European Society of Cardiology, Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention","volume":"35","author":"Aradi","year":"2014","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22214_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/ehjcvp\/pvab018","article-title":"The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy","volume":"8","author":"Magavern Ef","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"16","key":"10.1016\/j.heliyon.2023.e22214_bib8","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e22214_bib9","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1124\/jpet.106.110577","article-title":"Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol","volume":"319","author":"Tang","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"10.1016\/j.heliyon.2023.e22214_bib10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/FPC.0b013e3283385420","article-title":"Clopidogrel pathway","volume":"20","author":"Sangkuhl","year":"2010","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22214_bib11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/dmd.109.029132","article-title":"Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite","volume":"38","author":"Kazui","year":"2010","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22214_bib12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/0091270009343005","article-title":"Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans","volume":"50","author":"Farid","year":"2010","journal-title":"J. Clin. Pharmacol."},{"issue":"36","key":"10.1016\/j.heliyon.2023.e22214_bib13","doi-asserted-by":"crossref","first-page":"24749","DOI":"10.1074\/jbc.M114.583021","article-title":"Cysteines introduced into extracellular loops 1 and 4 of human P-glycoprotein that are close only in the open conformation spontaneously form a disulfide bond that inhibits drug efflux and ATPase activity","volume":"289","author":"Loo","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22214_bib14","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/jcpt.12236","article-title":"Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites","volume":"40","author":"Kara\u017aniewicz-\u0141ada","year":"2015","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22214_bib15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.clpt.6100052","article-title":"ABCB1 pharmacogenetics: progress, pitfalls, and promise","volume":"81","author":"Chinn","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e22214_bib16","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.clinthera.2019.04.037","article-title":"Influence of CYP450 enzymes, CES1, PON1, ABCB1, and P2RY12 polymorphisms on clopidogrel response in patients subjected to a percutaneous neurointervention","volume":"41","author":"Saiz-Rodr\u00edguez","year":"2019","journal-title":"Clin Ther"},{"issue":"3\u20134","key":"10.1016\/j.heliyon.2023.e22214_bib17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000442712","article-title":"P-glycoprotein polymorphism C3435T is associated with dose-adjusted clopidogrel and 2-oxo-clopidogrel concentration","volume":"97","author":"Stokanovic","year":"2016","journal-title":"Pharmacology"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e22214_bib18","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/jamaneurol.2018.4775","volume":"76","author":"Pan","year":"2019","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e22214_bib19","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"French registry of acute ST-elevation and non-ST-elevation myocardial infarction (FAST-MI) investigators, genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"9749","key":"10.1016\/j.heliyon.2023.e22214_bib20","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e22214_bib21","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4103\/0253-7613.186191","article-title":"Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults","volume":"48","author":"Sridharan","year":"2016","journal-title":"Indian J. Pharmacol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e22214_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039178","article-title":"Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese population","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22214_bib23","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/FJC.0000000000000767","article-title":"Impact of continuous P2Y12 inhibition tailoring in acute coronary syndrome and genetically impaired clopidogrel absorption","volume":"75","author":"Samardzic","year":"2020","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22214_bib24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/MBC.0000000000000536","article-title":"CYP2C19 but not CYP2B6, CYP3A4, CYP3A5, ABCB1, PON1 or P2Y12 genetic polymorphism impacts antiplatelet response after clopidogrel in Koreans","volume":"28","author":"Zhang","year":"2017","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e22214_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22369","article-title":"CYP2C19 and ABCB1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment","volume":"32","author":"Hou","year":"2018","journal-title":"J. Clin. Lab. Anal."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22214_bib26","first-page":"307","article-title":"Association of ABCB1 gene polymorphisms and clopidogrel responsiveness in Iranian patients undergoing percutaneous coronary intervention","volume":"19","author":"Namaz","year":"2020","journal-title":"Iran. J. Pharm. Res. (IJPR)"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e22214_bib27","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1124\/jpet.112.201640","article-title":"Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation","volume":"344","author":"Zhu","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e22214_bib28","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.ajhg.2008.04.015","article-title":"Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis","volume":"82","author":"Zhu","year":"2008","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22214_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FPC.0b013e32835aa8a2","article-title":"The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response","volume":"23","author":"Lewis","year":"2013","journal-title":"Pharmacogenet Genomics"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e22214_bib30","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/cpt.101","article-title":"Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans","volume":"97","author":"Tarkiainen","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e22214_bib31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/bcpt.12916","article-title":"Effects of genetic variants on carboxylesterase 1 gene expression, and clopidogrel pharmacokinetics and antiplatelet effects","volume":"122","author":"Neuvonen","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.heliyon.2023.e22214_bib32","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejps.2015.10.024","article-title":"Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults","volume":"82","author":"Jiang","year":"2016","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e22214_bib33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/ehjcvp\/pvz045","article-title":"ICPC Investigators. Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients","volume":"6","author":"Lewis","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22214_bib34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/cts.12383","article-title":"Genetic and nongenetic factors affecting clopidogrel response in the Egyptian population","volume":"9","author":"Khalil","year":"2016","journal-title":"Clin Transl Sci"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e22214_bib35","article-title":"Effects of the rs2244613 polymorphism of the CES1 gene on the antiplatelet effect of the receptor P2Y12 blocker clopidogrel","volume":"34","author":"Mirzaev","year":"2019","journal-title":"Drug Metab Pers Ther"},{"issue":"9","key":"10.1016\/j.heliyon.2023.e22214_bib36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/FPC.0000000000000349","article-title":"Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians","volume":"28","author":"Fathy","year":"2018","journal-title":"Pharmacogenet Genomics"},{"issue":"3\u20134","key":"10.1016\/j.heliyon.2023.e22214_bib37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000521531","article-title":"Influence of clinically significant genes on antiplatelet effect of clopidogrel and clinical outcomes in patients with acute coronary syndrome and atrial fibrillation","volume":"107","author":"Baturina","year":"2022","journal-title":"Pharmacology"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22214_bib38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/ng0193-73","article-title":"The molecular basis of the human serum paraoxonase activity polymorphism","volume":"3","author":"Humbert","year":"1993","journal-title":"Nat. Genet."},{"issue":"22","key":"10.1016\/j.heliyon.2023.e22214_bib39","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1161\/01.CIR.0000070954.00271.13","article-title":"Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study","volume":"107","author":"Mackness","year":"2003","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22214_bib40","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nm.2281","article-title":"Paraoxonase-1 is a major determinant of clopidogrel efficacy","volume":"17","author":"Bouman","year":"2011","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22214_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052779","article-title":"Paraoxonase 1 gene polymorphism does not affect clopidogrel response variability but is associated with clinical outcome after PCI","volume":"8","author":"Park","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2023.e22214_bib42","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/3470145","article-title":"Both CYP2C19 and PON1 Q192R genotypes influence platelet response to clopidogrel by thrombelastography in patients with acute coronary syndrome","volume":"2019","author":"Peng W","year":"2019","journal-title":"Cardiovasc Ther"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e22214_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254067","article-title":"PON1 Q192R is associated with high platelet reactivity with clopidogrel in patients undergoing elective neurointervention: a prospective single-center cohort study","volume":"16","author":"Tanaka","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22214_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40360-019-0378-7","article-title":"The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention","volume":"21","author":"Zhang","year":"2020","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e22214_bib45","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.thromres.2013.08.004","article-title":"PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity","volume":"132","author":"Li","year":"2013","journal-title":"Thromb. Res."},{"key":"10.1016\/j.heliyon.2023.e22214_bib46","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.atherosclerosis.2016.07.901","article-title":"Relationship of paraoxonase-1 Q192R genotypes and in-stent restenosis and re-stenting in Chinese patients after coronary stenting","volume":"251","author":"Ma","year":"2016","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e22214_bib47","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1161\/CIRCINTERVENTIONS.111.963025","article-title":"CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients","volume":"4","author":"Hulot","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e22214_bib48","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s11239-015-1264-9","article-title":"PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes","volume":"41","author":"Mega","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.heliyon.2023.e22214_bib49","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2147\/VHRM.S330766","article-title":"Association between paraoxonase-1 p.Q192R polymorphism and coronary artery disease susceptibility in the Colombian population","volume":"17","author":"Corredor-Orlandelli","year":"2021","journal-title":"Vasc. Health Risk Manag."},{"issue":"13","key":"10.1016\/j.heliyon.2023.e22214_bib50","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/eurheartj\/ehr155","article-title":"No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting","volume":"32","author":"Sibbing","year":"2011","journal-title":"Eur. Heart J."},{"issue":"19","key":"10.1016\/j.heliyon.2023.e22214_bib51","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","article-title":"Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes","volume":"119","author":"Mega","year":"2009","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e22214_bib52","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e22214_bib53","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1161\/STROKEAHA.113.000823","article-title":"CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China","volume":"44","author":"Jia","year":"2013","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22214_bib54","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/17512433.2017.1353909","article-title":"Role of genetic testing in patients undergoing percutaneous coronary intervention","volume":"11","author":"Moon","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e22214_bib55","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/cpt.2526","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update","volume":"112","author":"Lee","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e22214_bib56","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/0963689719851769","article-title":"Anti-platelet therapy in mild cerebral infarction patients on the basis of CYP2C19 metabolizer status","volume":"28","author":"Lan","year":"2019","journal-title":"Cell Transplant."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e22214_bib57","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2217\/pgs-2020-0046","article-title":"CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls","volume":"21","author":"Ellithi","year":"2020","journal-title":"Pharmacogenomics"},{"issue":"22","key":"10.1016\/j.heliyon.2023.e22214_bib58","doi-asserted-by":"crossref","first-page":"15419","DOI":"10.1016\/S0021-9258(17)40694-6","article-title":"The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans","volume":"269","author":"de Morais","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e22214_bib59","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.007811","article-title":"Clopidogrel pharmacogenetics","volume":"12","author":"Pereira","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"issue":"12","key":"10.1016\/j.heliyon.2023.e22214_bib60","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","article-title":"Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel","volume":"5","author":"Brandt","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e22214_bib61","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/bcp.14317","article-title":"Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta-analysis","volume":"86","author":"Yoon","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e22214_bib62","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/FJC.0000000000000577","article-title":"CYP2C19 genotype is an independent predictor of adverse cardiovascular outcome in Iraqi patients on clopidogrel after percutaneous coronary intervention","volume":"71","author":"Mohammad","year":"2018","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e22214_bib63","article-title":"The correlation between recurrent risk and CYP2C19 gene polymorphisms in patients with ischemic stroke treated with clopidogrel for prevention","volume":"99","author":"Liu","year":"2020","journal-title":"Medicine (Baltim.)"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22214_bib64","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1038\/s41598-021-85580-0","article-title":"Association between CYP2C19 polymorphisms and clinical outcomes in patients undergoing stent procedure for cerebral artery stenosis","volume":"11","author":"Li","year":"2021","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e22214_bib65","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1007\/s00228-021-03176-z","article-title":"The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention","volume":"77","author":"Wang","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e22214_bib66","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2217\/pgs-2021-0098","article-title":"Effects of the CYP2C19 LoF allele on major adverse cardiovascular events associated with clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis","volume":"23","author":"Biswas","year":"2022","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22214_bib67","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/09537104.2017.1413178","article-title":"CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: a systematic review and meta-analysis","author":"Xi","year":"2019","journal-title":"Platelets"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22214_bib68","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bcpt.12763","article-title":"The CYP2C19*2 and CYP2C19*17 polymorphisms play a vital role in clopidogrel responsiveness after percutaneous coronary intervention: a pharmacogenomics study","volume":"121","author":"Saydam","year":"2017","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e22214_bib69","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/aps.2016.41","article-title":"Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke","volume":"37","author":"Liu","year":"2016","journal-title":"Acta Pharmacol. Sin."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e22214_bib70","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2217\/pme-2018-0030","article-title":"Cytochrome 2C19 and paraoxonase-1 polymorphisms and clopidogrel resistance in ischemic heart disease patients","volume":"16","author":"Akram","year":"2019","journal-title":"Per Med"},{"key":"10.1016\/j.heliyon.2023.e22214_bib71","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.12659\/MSM.915971","article-title":"Association of CYP2C19 polymorphism with clopidogrel resistance in patients with acute coronary syndrome in China","volume":"25","author":"Su","year":"2019","journal-title":"Med Sci Monit"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e22214_bib72","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/FJC.0000000000000627","article-title":"Investigating the effect of demographics, clinical characteristics, and polymorphism of MDR-1, CYP1A2, CYP3A4, and CYP3A5 on clopidogrel resistance","volume":"72","author":"Al-Husein","year":"2018","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22214_bib73","first-page":"123","article-title":"Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients","volume":"19","author":"Zhuo","year":"2018","journal-title":"Anatol. J. Cardiol."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e22214_bib74","first-page":"e123","volume":"134","author":"Levine","year":"2016","journal-title":"and 2014 ACC\/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery, Circulation"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e22214_bib75","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e22214_bib76","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.CIR.0000085073.69189.88","article-title":"Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects","volume":"108","author":"Fontana","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.heliyon.2023.e22214_bib77","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4103\/1735-1995.193502","article-title":"Relationship between clopidogrel-related polymorphisms and variable platelet reactivity at 1 year: a cohort study from Han Chinese","volume":"21","author":"Wang","year":"2016","journal-title":"J. Res. Med. Sci."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22214_bib78","doi-asserted-by":"crossref","first-page":"343","DOI":"10.17219\/acem\/63745","article-title":"P2Y12 receptor gene polymorphism and the risk of resistance to clopidogrel: a meta-analysis and review of the literature","volume":"26","author":"Cui","year":"2017","journal-title":"Adv. Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22214_bib79","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1631\/jzus.B1600333","article-title":"Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity","volume":"18","author":"Nie","year":"2017","journal-title":"J. Zhejiang Univ. - Sci. B"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e22214_bib80","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.thromres.2007.01.012","article-title":"Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome","volume":"120","author":"Cuisset","year":"2007","journal-title":"Thromb. Res."},{"issue":"15","key":"10.1016\/j.heliyon.2023.e22214_bib81","article-title":"Association of clopidogrel high on-treatment reactivity with clinical outcomes and gene polymorphism in acute ischemic stroke patients: an observational study","volume":"99","author":"Fu","year":"2020","journal-title":"Medicine (Baltim.)"},{"issue":"14","key":"10.1016\/j.heliyon.2023.e22214_bib82","article-title":"Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome","volume":"96","author":"Li","year":"2017","journal-title":"Medicine (Baltim.)"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22214_bib83","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/a-0622-8110","article-title":"P2Y12 polymorphisms and the risk of adverse clinical events in patients treated with clopidogrel: a meta-analysis","volume":"69","author":"hao","year":"2019","journal-title":"Drug Res."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e22214_bib84","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1124\/dmd.110.037143","article-title":"In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics","volume":"39","author":"Zhou","year":"2011","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22214_bib85","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/cpt.1177","article-title":"CYP3A4*22 impairs the elimination of ticagrelor, but has No significant effect on the bioactivation of clopidogrel or prasugrel","volume":"105","author":"Holmberg","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22214_bib86","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/bcpt.13884","article-title":"CYP3A4*22 may increase bleeding risk in ticagrelor users","volume":"133","author":"Liedes","year":"2023","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.heliyon.2023.e22214_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1032995","article-title":"Effects of CYP3A4*22 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study","volume":"13","author":"Azzahhafi","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2023.e22214_bib88","first-page":"176","article-title":"Effect of CYP3A4\u22171G and CYP3A5\u22173 polymorphisms on pharmacokinetics and pharmacodynamics of ticagrelor in healthy Chinese subjects","volume":"8","author":"Liu","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e22214_bib89","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00228-018-2427-3","article-title":"Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects","volume":"74","author":"Liu","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22214_bib90","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1248\/bpb.b16-00686","article-title":"No effect of SLCO1B1 and CYP3A4\/5 polymorphisms on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy Chinese male subjects","volume":"40","author":"Li","year":"2017","journal-title":"Biol. Pharm. Bull."},{"issue":"9749","key":"10.1016\/j.heliyon.2023.e22214_bib91","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"PLATO investigators, Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2023.e22214_bib92","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3389\/fphar.2019.00209","article-title":"Pharmacokinetic and pharmacogenetic factors contributing to platelet function recovery after single dose of ticagrelor in healthy subjects","volume":"10","author":"Zhu","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e22214_bib93","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/CIRCGENETICS.110.958561","article-title":"First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET\/OFFSET and RESPOND genotype studies","volume":"3","author":"Tantry","year":"2010","journal-title":"Circ Cardiovasc Genet"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e22214_bib94","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/00498254.2020.1731625","article-title":"CYP2C19 and CYP3A4 activity and ADP-induced platelet reactivity in prasugrel- or ticagrelor-treated STEMI patients: monocentric study in PRAGUE-18 trial participants","volume":"50","author":"M\u00e1chal","year":"2020","journal-title":"Xenobiotica"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e22214_bib95","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/09537100903075324","article-title":"Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3","volume":"20","author":"Storey","year":"2009","journal-title":"Platelets"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e22214_bib96","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3390\/ijerph14030301","article-title":"Pharmacokinetic and pharmacodynamic responses to clopidogrel: evidences and perspectives","volume":"14","author":"Zhang","year":"2017","journal-title":"Int. J. Environ. Res. Publ. Health"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e22214_bib97","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2217\/pgs.14.165","article-title":"Effect of clinical factors and gene polymorphism of CYP2C19*2, *17 and CYP4F2*3 on early stent thrombosis","volume":"16","author":"Kupstyte","year":"2015","journal-title":"Pharmacogenomics"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e22214_bib98","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/MBC.0000000000000053","article-title":"The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy","volume":"25","author":"Tatarunas","year":"2014","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"10","key":"10.1016\/j.heliyon.2023.e22214_bib99","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2217\/pgs-2017-0070","article-title":"The impact of clinical and genetic factors on ticagrelor and clopidogrel antiplatelet therapy","volume":"18","author":"Tatarunas","year":"2017","journal-title":"Pharmacogenomics"},{"issue":"7","key":"10.1016\/j.heliyon.2023.e22214_bib100","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2217\/pgs-2018-0178","article-title":"The impact of CYP2C19 and CYP4F2 variants and clinical factors on treatment outcomes during antiplatelet therapy","volume":"20","author":"Tatarunas","year":"2019","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22214_bib101","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/bcpt.13884","article-title":"CYP3A4*22 may increase bleeding risk in ticagrelor users","volume":"133","author":"Liedes","year":"2023","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.heliyon.2023.e22214_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.797278","article-title":"Effect of CYP4F2 polymorphisms on ticagrelor pharmacokinetics in healthy Chinese volunteers","volume":"12","author":"Nie","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22214_bib103","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/1074248411410883","article-title":"Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model","volume":"17","author":"van Giezen","year":"2012","journal-title":"J. Cardiovasc. Pharmacol. Therapeut."},{"issue":"23","key":"10.1016\/j.heliyon.2023.e22214_bib104","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1182\/blood-2016-03-707844","article-title":"Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor","volume":"128","author":"Aungraheeta","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.heliyon.2023.e22214_bib105","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/jth.12360","article-title":"Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism","volume":"11","author":"Nylander","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22214_bib106","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1074248413511693","article-title":"Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1","volume":"19","author":"Armstrong","year":"2014","journal-title":"J. Cardiovasc. Pharmacol. Therapeut."},{"key":"10.1016\/j.heliyon.2023.e22214_bib107","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.phrs.2017.12.035","article-title":"Novara Atherosclerosis Study Group (NAS), Impact of adenosine A2a receptor polymorphism rs5751876 on platelet reactivity in ticagrelor treated patients","volume":"129","author":"Nardin","year":"2018","journal-title":"Pharmacol. Res."},{"issue":"29","key":"10.1016\/j.heliyon.2023.e22214_bib108","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/eurheartj\/ehv116","article-title":"PLATO Investigators, Effect of genetic variations on ticagrelor plasma levels and clinical outcomes","volume":"36","author":"Varenhorst","year":"2015","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e22214_bib109","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12185-014-1502-5","article-title":"Association of platelet ITGA2B and ITGB3 polymorphisms with ex vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects","volume":"99","author":"Li","year":"2014","journal-title":"Int. J. Hematol."},{"issue":"26","key":"10.1016\/j.heliyon.2023.e22214_bib110","doi-asserted-by":"crossref","first-page":"24680","DOI":"10.1074\/jbc.M413411200","article-title":"Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contact-induced activation","volume":"280","author":"Nanda","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e22214_bib111","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1080\/00498254.2016.1271962","article-title":"Association of PEAR1 rs12041331 polymorphism and pharmacodynamics of ticagrelor in healthy Chinese volunteers","volume":"47","author":"Li","year":"2017","journal-title":"Xenobiotica"},{"key":"10.1016\/j.heliyon.2023.e22214_bib112","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3389\/fphar.2018.00490","article-title":"Variants of PEAR1 are associated with outcome in patients with ACS and stable CAD undergoing PCI","volume":"9","author":"Stimpfle","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"24","key":"10.1016\/j.heliyon.2023.e22214_bib113","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/eurheartj\/ehv229","article-title":"Genetic testing to guide therapy? Not for ticagrelor","volume":"40","author":"Hengstenberg","year":"2019","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e22214_bib114","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1124\/dmd.105.007989","article-title":"Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450","volume":"34","author":"Rehmel","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e22214_bib115","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/00498254.2020.1731625","article-title":"CYP2C19 and CYP3A4 activity and ADP-induced platelet reactivity in prasugrel- or ticagrelor-treated STEMI patients: monocentric study in PRAGUE-18 trial participants","volume":"50","author":"M\u00e1chal","year":"2020","journal-title":"Xenobiotica"},{"issue":"7","key":"10.1016\/j.heliyon.2023.e22214_bib116","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.amjcard.2012.12.013","article-title":"Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications","volume":"111","author":"Grosdidier","year":"2013","journal-title":"Am. J. Cardiol."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e22214_bib117","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.jcin.2012.07.015","article-title":"CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome","volume":"5","author":"Cuisset","year":"2012","journal-title":"JACC Cardiovasc. Interv."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e22214_bib118","first-page":"589","article-title":"The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease","volume":"112","author":"Gurbel","year":"2014","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e22214_bib119","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s11239-018-1714-2","article-title":"Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel","volume":"46","author":"Kitazono","year":"2018","journal-title":"J. Thromb. Thrombolysis"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e22214_bib120","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/1440-1681.12390","article-title":"Prevalence of CYP2C19 alleles, pharmacokinetic and pharmacodynamic variation of clopidogrel and prasugrel in Bangladeshi population","volume":"42","author":"Bin Sayeed","year":"2015","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.heliyon.2023.e22214_bib121","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/B978-0-12-386930-2.00006-9","article-title":"Genetics of response to antiplatelet therapy","volume":"124","author":"Thomas","year":"2014","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e22214_bib122","first-page":"1223","article-title":"Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways","volume":"110","author":"Braun","year":"2013","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22214_bib123","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1160\/TH13-01-0021","article-title":"Cytochrome P450 2B6 and 2C9 genotype polymorphism--a possible cause of prasugrel low responsiveness","volume":"110","author":"Franken","year":"2013","journal-title":"Thromb Haemost"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e22214_bib124","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3109\/09537104.2013.852659","article-title":"First report of a subacute stent thrombosis in a prasugrel resistant patient successfully managed with ticagrelor","volume":"25","author":"Fiore","year":"2014","journal-title":"Platelets"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e22214_bib125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ehjcr\/ytaa137","article-title":"Acute thrombosis of everolimus-eluting platinum chromium stent caused by impaired prasugrel metabolism due to cytochrome P450 enzyme 2B6*2 (C64T) polymorphism: a case report","volume":"4","author":"Yamagata","year":"2020","journal-title":"Eur Heart J Case Rep"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22214_bib126","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2125.2011.04049.x","article-title":"Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants","volume":"73","author":"Kelly","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2023.e22214_bib127","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/jth.12231","article-title":"Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC\/isth","volume":"11","author":"Cattaneo","year":"2013","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e22214_bib129","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3390\/jcm9030763","article-title":"Strengths and weaknesses of light transmission aggregometry in diagnosing hereditary platelet function disorders","volume":"9","author":"Alessi","year":"2020","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22214_bib128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.blre.2004.05.002","article-title":"Platelet function analysis","volume":"19","author":"Harrison","year":"2005","journal-title":"Blood Rev."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22214_bib130","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/FTD.0b013e3182052ff4","article-title":"Light transmittance aggregometry induced by different concentrations of adenosine diphosphate to monitor clopidogrel therapy: a methodological study","volume":"33","author":"Paniccia","year":"2011","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.heliyon.2023.e22214_bib131","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.cca.2021.06.019","article-title":"Comparison between thromboelastography and conventional coagulation assays in patients with deep vein thrombosis","volume":"520","author":"Mao","year":"2021","journal-title":"Clin. Chim. Acta"},{"issue":"12","key":"10.1016\/j.heliyon.2023.e22214_bib132","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1373\/clinchem.2014.226332","article-title":"Precision and reliability of 5 platelet function tests in healthy volunteers and donors on daily antiplatelet agent therapy","volume":"60","author":"Karon","year":"2014","journal-title":"Clin. Chem."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e22214_bib133","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2174\/1567202617999200819161033","article-title":"Microbleeds after stent-assisted coil embolization of unruptured intracranial aneurysms: incidence, risk factors and the role of thromboelastography","volume":"17","author":"Xu","year":"2020","journal-title":"Curr Neurovasc Res"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22214_bib134","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ahj.2010.05.034","article-title":"Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events","volume":"160","author":"Gurbel","year":"2010","journal-title":"Am. Heart J."},{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2023.e22214_bib135","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1538-7836.2007.02498.x","article-title":"Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection","volume":"5","author":"Cattaneo","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22214_bib136","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1160\/TH07-09-0555","article-title":"A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry","volume":"99","author":"Jakubowski","year":"2008","journal-title":"Thromb Haemost"},{"issue":"21","key":"10.1016\/j.heliyon.2023.e22214_bib137","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.jacc.2012.11.080","article-title":"Platelet function tests in clinical cardiology: unfulfilled expectations","volume":"61","author":"Gorog","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e22214_bib138","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.2337\/db07-0707","article-title":"The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study","volume":"56","author":"DiChiara","year":"2007","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e22214_bib139","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/09537104.2018.1499887","article-title":"Comparison of factors affecting platelet reactivity in various platelet function tests","volume":"30","author":"Choi","year":"2019","journal-title":"Platelets"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22214_bib140","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3109\/14017431.2011.629677","article-title":"Correlation between point-of-care platelet function testing and bleeding after coronary artery surgery","volume":"46","author":"Dal\u00e9n","year":"2012","journal-title":"Scand. Cardiovasc. J."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e22214_bib141","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1080\/09537104.2018.1492109","article-title":"Platelet aggregation measured by single-platelet counting and using PFA-100 devices","volume":"29","author":"Dovlatova","year":"2018","journal-title":"Platelets"},{"issue":"7","key":"10.1016\/j.heliyon.2023.e22214_bib142","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s11739-015-1242-4","article-title":"Dual antiplatelet therapy tailored on platelet function test after coronary stent implantation: a real-world experience","volume":"10","author":"Cecchi","year":"2015","journal-title":"Intern Emerg Med"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22214_bib143","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12959-022-00380-4","article-title":"Prediction of residual ischemic risk in ticagrelor-treated patients with acute coronary syndrome","volume":"20","author":"Zou Y","year":"2022","journal-title":"Thromb. J."},{"key":"10.1016\/j.heliyon.2023.e22214_bib144","first-page":"201","article-title":"Cardiovascular Laboratory Medicine Committee of the Chinese Medical Doctor Association Laboratory Physicians Branch, Expert consensus on the use of platelet function tests in antiplatelet therapy in patients with acute coronary syndrome","volume":"3","year":"2018","journal-title":"Clinical Medical Research and Practice"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e22214_bib146","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2010.181","article-title":"Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation","volume":"303","author":"Breet","year":"2010","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.heliyon.2023.e22214_bib147","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/j.1538-7836.2012.04875.x","article-title":"Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel","volume":"10","author":"Bonello","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e22214_bib148","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcin.2020.01.226","article-title":"Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score","volume":"13","author":"Angiolillo","year":"2020","journal-title":"JACC Cardiovasc. Interv."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e22214_bib149","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024156","article-title":"ABCD-GENE score and clinical outcomes following percutaneous coronary intervention: insights from the TAILOR-PCI trial","volume":"11","author":"Capodanno","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.heliyon.2023.e22214_bib150","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijcard.2020.11.022","article-title":"Validation of the ABCD-GENE score to identify high platelet reactivity in east Asian patients undergoing percutaneous coronary intervention","volume":"327","author":"Saito","year":"2021","journal-title":"Int. J. Cardiol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e22214_bib151","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s12265-022-10255-8","article-title":"Performance of the ABCD-GENE score for predicting clinical outcomes in clopidogrel-treated patients with ACS","volume":"15","author":"Jin","year":"2022","journal-title":"J Cardiovasc Transl Res"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22214_bib152","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/STROKEAHA.120.033049","article-title":"Application of age, body mass index, chronic kidney disease, diabetes, and genotyping score for efficacy of clopidogrel: secondary analysis of the CHANCE trial","volume":"53","author":"Dai","year":"2022","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22214_bib153","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/cpt.2612","article-title":"Impact of the ABCD-GENE score on clopidogrel clinical effectiveness after PCI: a multi-site, real-world investigation","volume":"112","author":"Thomas","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2023.e22214_bib154","article-title":"Development and validation of a novel tool for the prediction of clopidogrel response in Chinese acute coronary syndrome patients: the GeneFA score","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e22214_bib155","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00228-019-02696-z","article-title":"Tailored P2Y12 inhibitor treatment in patients undergoing non-urgent PCI-the POPular Risk Score study","volume":"75","author":"Janssen","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e22214_bib156","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-038936","article-title":"Implementing a pharmacogenetic-driven algorithm to guide dual antiplatelet therapy (DAPT) in Caribbean Hispanics: protocol for a non-randomised clinical trial","volume":"10","author":"Hernandez-Suarez","year":"2020","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22214_bib157","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00228-021-03224-8","article-title":"Utility of a pharmacogenetic-driven algorithm in guiding dual antiplatelet therapy for patients undergoing coronary drug-eluting stent implantation in China","volume":"78","author":"Lyu","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e22214_bib158","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/AC.70.5.3110511","article-title":"STIB investigators, the STIB score: a simple clinical test to predict clopidogrel resistance","volume":"70","author":"Legrand","year":"2015","journal-title":"Acta Cardiol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22214_bib159","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/jpm8010008","article-title":"Pharmacogenomic impact of CYP2C19 variation on clopidogrel therapy in precision cardiovascular medicine","volume":"8","author":"Brown","year":"2018","journal-title":"J Pers Med"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e22214_bib160","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1111\/cts.13124","article-title":"Pharmacogenomic polygenic risk score for clopidogrel responsiveness among Caribbean Hispanics: a candidate gene approach","volume":"14","author":"Duconge","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"11","key":"10.1016\/j.heliyon.2023.e22214_bib161","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.5551\/jat.63300","article-title":"Derivation of a novel scoring system predicting high platelet reactivity on prasugrel in patients with coronary artery disease","volume":"29","author":"Saito","year":"2022","journal-title":"J Atheroscler Thromb"},{"issue":"17","key":"10.1016\/j.heliyon.2023.e22214_bib162","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jacc.2013.05.082","article-title":"Mechanisms affecting platelet response to antiplatelet therapy in patients with ST-segment elevation myocardial infarction","volume":"62","author":"Siasos","year":"2013","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023094227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023094227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:10:20Z","timestamp":1774951820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023094227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":161,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2405844023094227"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e22214","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances and Perspectives in methods for identifying high platelet reactivity","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e22214","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e22214"}}